Physician profile
David B Glazier
NPI 1427011329
$7,425.41
in general payments reported to CMS, 2019-2025
38 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $1,020 · 2021: $1,447 · 2022: $1,048 · 2023: $497 · 2024: $413 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,357.12 | 2019-2021 | |
| Caldera Medical, INC | $1,216.63 | 2019-2022 | |
| Intuitive Surgical, INC. | $781.35 | 2019-2022 | |
| Janssen Biotech, INC. | $550.69 | 2019-2025 | Erleada, Akeega |
| Abbvie INC. | $528.05 | 2021-2025 | |
| Allergan, INC. | $500.00 | 2020 | |
| Dendreon Pharmaceuticals LLC | $227.88 | 2020-2023 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $208.33 | 2021-2025 | |
| Blue Earth Diagnostics | $203.21 | 2021-2025 | Posluma |
| Boston Scientific Corporation | $182.00 | 2019-2025 | Rezum Generator |
| Medtronic USA, INC. | $131.73 | 2019 | |
| Urogen Pharma, INC. | $127.06 | 2022-2025 | Jelmyto |
| Astellas Pharma US INC | $126.19 | 2021-2025 | Xtandi |
| Endo USA, INC. | $119.83 | 2024-2025 | Aveed, Xiaflex |
| Novartis Pharmaceuticals Corporation | $117.13 | 2022-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $116.94 | 2023-2025 | Gemtesa, Orgovyx |
| Merck Sharp & Dohme LLC | $107.88 | 2020-2024 | Welireg, Keytruda, Lynparza |
| Amgen INC. | $80.39 | 2021-2023 | Prolia |
| Endo Pharmaceuticals INC. | $73.55 | 2022-2024 | Aveed, Xiaflex |
| Calyxo, INC. | $62.99 | 2025 | Cvac Aspiration System |
| Antares Pharma, INC. | $61.36 | 2020-2025 | Xyosted |
| Progenics Pharmaceuticals, INC. | $59.11 | 2023-2025 | Pylarify |
| Sun Pharmaceutical Industries INC. | $54.87 | 2023 | Yonsa |
| Ferring Pharmaceuticals INC. | $53.48 | 2024-2025 | Adstiladrin |
| Myovant Sciences INC. | $42.64 | 2022 | |
| Ambu INC. | $38.85 | 2022-2023 | |
| Photocure INC | $36.34 | 2019 | |
| Teleflex LLC | $35.84 | 2023-2025 | Barrigel, Urolift |
| Urovant Sciences INC | $35.52 | 2021-2022 | |
| Pfizer INC. | $32.15 | 2021-2022 | |
| Rochester Medical Corporation | $31.48 | 2019-2020 | |
| Halozyme INC | $24.52 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $20.16 | 2021 | |
| Procept Biorobotics Corporation | $19.93 | 2024 | Aquabeam System |
| Abc Home Medical Supply, INC. | $19.00 | 2025 | |
| Mission Pharmacal Company | $13.90 | 2019 | |
| Foundation Medicine, INC. | $13.69 | 2021 | |
| Accord Healthcare, INC. | $13.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Glazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.